Staff Writer: Deileta Kamhunga The survival rates of B-cell acute lymphoblastic leukemia (B-ALL) have been dramatically improved through relatively new therapies. One such therapy is CD19-directed chimeric antigen receptor T-cell (CART) therapy, which has improved survival rates, particularly in children with relapsed or refractory B-ALL. However, other external factors may also have a significant impact...